Screener
BillionToOne, Inc. BLLN Oncology — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BillionToOne, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: BillionToOne, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:42 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0002070849-26-000050
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Prenatal | $94,248 | $60,852 | $190,773 | $116,929 |
| Oncology | 13,663 | 4,947 | 24,383 | 7,123 |
| Clinical trial support and other services | 1,537 | 774 | 2,680 | 1,484 |
| Total revenues | $109,448 | $66,573 | $217,836 | $125,536 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BillionToOne, Inc.'s oncology — revenue?
- BillionToOne, Inc. (BLLN) reported oncology — revenue of $13.66M in Q2 2026.
- How has BillionToOne, Inc.'s oncology — revenue changed year-over-year?
- BillionToOne, Inc.'s oncology — revenue increased by 176.2% year-over-year, from $4.95M to $13.66M.
- What does oncology — revenue mean?
- This metric represents the total gross income generated from the sale of oncology-focused molecular diagnostic products and liquid biopsy testing services. It serves as a primary indicator of the company's market penetration and commercial adoption within the cancer diagnostics sector. Growth in this segment reflects the successful scaling of specialized clinical testing solutions and the expansion of the company's precision oncology portfolio.
Ask your AI about BillionToOne, Inc.'s oncology — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude